Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Primary Myelofibrosis × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 9 Neoplasms 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

ruxolitinib 5 fludarabine 3 Cyclophosphamide 3 Whole-Body Irradiation 2 Tacrolimus 2 Stem Cell Transplantation 2 Specimen Handling 2 venetoclax 1 veliparib 1 selinexor 1 pevonedistat 1 merphos 1 iadademstat 1 fludarabine phosphate 1 fedratinib 1 decitabine and cedazuridine drug combination 1 bomedemstat 1 Topotecan 1 Panobinostat 1 Mycophenolic Acid 1 Methotrexate 1 Melphalan 1 Janus Kinase Inhibitors 1 Injections 1 INCB057643 1 Granulocyte Colony-Stimulating Factor 1 Decitabine 1 Cyclosporine 1 Carboplatin 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡